Inhibition of AXL signaling in anti-metastatic therapy

US9266947B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Amato J. Giaccia · Stanford, US
• Erinn Bruno Rankin · Waltham, US
• Jennifer R. Cochran · Stanford, US
• Douglas Jones · Newton, US
• Mihalis Kariolis · South San Francisco, US
• Katherine Fuh · Chesterfield, US
• Yu Miao · Sunnyvale, US

Key dates

• Filing date: Jul 24, 2013
• Grant date: Feb 23, 2016
• Expiry date: Jul 24, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.